Contineum Therapeutics Inc

CTNM

Add to Watchlist

13.720USD

-0.490-3.45%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Contineum Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

14 / 382

Overall Ranking

99 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Contineum Therapeutics Inc Highlights

StrengthsRisks

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with significant unmet need. It is advancing a pipeline of internally developed programs with multiple drug candidates in clinical trials. Its lead asset, PIPE-791, is a novel, brain-penetrant, small-molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF), progressive multiple sclerosis (PrMS), and chronic pain. Its second drug candidate, PIPE-307, is a novel, small-molecule selective inhibitor of the muscarinic type 1 receptor (M1R), in development for depression and relapse-remitting multiple sclerosis (RRMS). The Company is also conducting preclinical and discovery-phase experiments targeting other NI&I indications where its internally discovered molecules may have therapeutic potential.

Undervalued

The company’s latest PE is -7.09, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 29.78M shares, increasing 25.52% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 57.10K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.42.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

22.333

Target Price

+57.17%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Contineum Therapeutics Inc is 8.74, ranking 26 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.74

Change

0



Financials

8.50

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.47

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.74

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Contineum Therapeutics Inc is 6.70, ranking 224 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.09, which is -485.28% below the recent high of 27.33 and -148.22% above the recent low of -17.61.

Score

Industry at a Glance

Previous score

6.70

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 14/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Contineum Therapeutics Inc is 8.86, ranking 44 out of 382 in the Biotechnology & Medical Research industry. The average price target is 22.00, with a high of 29.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.86

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Contineum Therapeutics Inc is 7.07, ranking 105 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 15.66 and the support level at 11.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.24

Change

-0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Suvretta Capital Management, LLC

2.84M

+65.19%

Janus Henderson Investors

2.45M

--

RA Capital Management, LP

2.18M

+2.72%

Johnson & Johnson Innovation-JJDC, Inc.

1.98M

--

Franklin Advisers, Inc.

1.88M

+13.52%

Balyasny Asset Management LP

1.84M

+93.71%

Millennium Management LLC

830.69K

+28.58%

Perceptive Advisors LLC

1.46M

+104.95%

Baker Bros. Advisors LP

1.42M

+1729.33%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Contineum Therapeutics Inc is 3.43, ranking 136 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Contineum Therapeutics Inc

CTNM

7.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment